FDA approves expanded use of Adacel vaccine

Press enter to search
Close search
Open Menu

FDA approves expanded use of Adacel vaccine

By Sandra Levy - 01/15/2019
Patients now have an extra safeguard against tetanus, diphtheria and pertussis.

Sanofi Pasteur has received the Food and Drug Administration’s blessing for the expanded use of Adacel (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis.

It is now the first and only Tdap vaccine in the United States approved for a repeat dose in people between the ages of 10-to-64 years old, administered eight or more years after the first vaccination. Adacel also is the only Tdap vaccine available in a syringe made without natural rubber latex, which the company said may help reduce risk to patients with an allergy.

"While strong vaccination programs are in place for young adolescents, a single Tdap immunization does not offer lifetime protection against pertussis due to waning immunity," Sanofi Pasteur regional medical head of North America David Greenberg said. "The licensure of Adacel as the first Tdap vaccine in the U.S. for repeat vaccination is an important step for eligible patients, and offers flexibility for healthcare providers to help manage their immunization schedules."

Related Topics